20 miliardi di euro l’anno: i costi per il cancro in Italia – Prevenzione attiva, la vera arma vincente
The potential development of the IMMUNEBALANCE technology is related to the possible upgrade made by the supplier of the equipment (flow cytometry or others). The AI that will integrate the IMMUNEBALANCE results with the anamnestic data and the results of the other HELIXAFE tests will be developed in WP1; it will provide our customers with a completely automated, reliable output, and will automatically get updated and fine-tuned, by the feeds of the newly collected data. In WP2, we will validate the ability of our AI to integrate the IMMUNEBALANCE results with anamnestic data and the results of the other HELIXAFE tests, to be able to outline an individual’s colorectal cancer risk profile.
